## Phase I Study of Chimeric Antigen Receptor Engineered Central Memory T cells for the Treatment of Malignant Glioma

**Disease Area:** Brain Cancer  
**Investigator:** Christine Brown  
**Institution:** City of Hope, Beckman Research Institute  
**CIRM Grant:** CLIN2-10248  
**Award Value:** $12,753,854  
**Trial Sponsor:** Beckman Research Institute of City of Hope  
**Trial Stage:** Phase 1  
**Trial Status:** Recruiting  
**Targeted Enrollment:** 92  
**ClinicalTrials.gov ID:** NCT02208362

### Details:
A team at the City of Hope led by Dr. Christine Brown is pursuing a Phase 1 trial targeting an aggressive brain cancer called malignant glioma. City of Hope will re-engineer a patient’s immune system central memory T cells (TCM cells) to express chimeric antigen receptors (CAR). These CAR-T cells will recognize a molecular marker on the surface of glioma cancer stem cells and kill the tumors. Dr. Brown’s award to pursue CAR-T therapy for solid cancers comes at an exciting and opportune time with the recent U.S. Food and Drug Administration (FDA) approval of the first CAR-T therapy, called Kymriah, for patients with acute lymphoblastic leukemia, a deadly form of blood cancer.

### Design:
Non-randomized, open-label treatment.

### Goal:
Determine safety, feasibility, and efficacy.

### News about this clinical trial:
City of Hope Scientist Christine Brown Receives $12.8M Grant from CIRM to Fund Trial for Brain Cancer

Contact Trial Sponsor